GlassScriptPhysician profile
Amy T Moore
NPI 1013553197
$5,854.67
in general payments reported to CMS, 2019-2025
25 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,680 · 2023: $1,953 · 2024: $2,084 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,160 · Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,160.00 |
| Food and Beverage | $2,015.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,138.45 | 2022-2024 | Venacure 1470 Pro, Alphavac |
| Merck Sharp & Dohme LLC | $414.76 | 2022-2024 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $305.74 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.83 | 2022-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $220.25 | 2023-2024 | |
| Amgen INC. | $196.59 | 2022-2024 | Repatha |
| Esperion Therapeutics, INC. | $142.94 | 2022-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.08 | 2023-2024 | Jardiance |
| United Therapeutics Corporation | $133.42 | 2022-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $117.61 | 2022-2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $117.18 | 2022-2024 | Amvuttra |
| Daiichi Sankyo INC. | $108.21 | 2022-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $94.28 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $84.97 | 2022-2023 | |
| Pfizer INC. | $74.57 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65.09 | 2022-2023 | Farxiga, Brilinta |
| Scpharmaceuticals INC. | $60.92 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $41.01 | 2024 | Arcalyst |
| Chiesi USA, INC. | $35.15 | 2022-2024 | Juxtapid |
| Azurity Pharmaceuticals, INC. | $31.74 | 2023 | Edarbyclor |
| Boston Scientific Corporation | $22.79 | 2024 | Watchman Access System |
| Abbott Laboratories | $21.13 | 2022 | |
| Irhythm Technologies, INC. | $17.86 | 2022 | |
| Philips North America LLC | $14.91 | 2025 | Igt Devices Systems Undivided |
| Cvrx, INC. | $7.19 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.